Close
MONITOR-Breast: Monitoring cell-free tumor DNA as a marker of recurrence in Breast Cancer
This is a prospective, observational study designed to evaluate the clinical validity of Myriad Genetics’ MRD test in patients diagnosed with breast cancer. It is expected that enrollment will be split between the different breast cancer subtypes defined by immunohistochemistry (HR+/HER2-, HER2+ (HR+ and HR-), TNBC) and according to BINV-A of National Comprehensive Cancer Network guidelines with ER+ status used here as >10% of nuclei staining.
Mays Cancer Center researchers to present findings, discuss disparities during San Antonio Breast Cancer Symposium
Researchers from the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, will present results of multiple lines of study Dec. 7-10 during the 2021 San Antonio Breast Cancer Symposium.
Mays Cancer Center hosts annual breast cancer symposium, addresses care and advancements in treatment
Mays Cancer Center at UT Health San Antonio, in partnership with the American Association for Cancer Research (AACR), is hosting the 46th annual San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center on Dec. 5-9. This scientific and education symposium, initiated and owned by Mays Cancer Center, is the world’s largest […]
How genetic testing could determine your risk of getting breast cancer
Natalie Poullard, MA, MS, CGC, a certified genetic counselor at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, provides a brief understanding of genetic testing benefits, the types of tests available and what you can expect during an appointment. Watch here
Stereotactic Body Radiotherapy (SBRT)
At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, our radiation oncologists combine advanced technologies with exceptional cancer expertise.
Mays Cancer Center led studies of innovative breast cancer drug that recently gained FDA approval
The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, was the lead site for a study evaluating Phase I and Phase III clinical trials for elacestrant, a treatment for postmenopausal women and adult men with ER+/HER2- advanced or metastatic breast cancer. The U.S. Food and Drug Administration on Jan. 27 announced it approved the […]
David Gius receives UT System award to advance research on aging and breast cancer
David Gius, MD, PhD, has been awarded a $1.6 million UT System Faculty STARs award to support his research on aging and breast cancer.
Screenings & Diagnosis
Screening & Diagnosis